IntraGel Therapeutics

IntraGel Therapeutics is a dynamic pharmaceutical company committed to revolutionizing anti-neoplasm treatment through innovative drug delivery systems. With a focus on long-acting and localized delivery of challenging small molecule drugs, peptides, and other anti-neoplasm agents, IntraGel Therapeutics is dedicated to improving patient outcomes and quality of life.

IntraGel Therapeutics has developed SRGel, a unique injectable polymeric platform for sustained release. Once injected, this platform solidifies and slowly breaks down over weeks, releasing the trapped drug or agent to the surrounding area. The IntraGel platform, based on fatty acids, is hydrophobic and solventless, making it a versatile solution for a wide range of drugs, including sensitive and insoluble ones. IntraGel Therapeutics is located at Wadi El Haj, 13, Nazareth, IL, and is strategically positioned to address critical needs in oncology.

With a significant market potential in oncology, IntraGel Therapeutics is initially targeting head and neck cancer (HNC), where a substantial unmet need exists for patients unfit for conventional systemic chemotherapy. The IntraGel platform allows for a simple application through direct intratumoral injection, offering a long-acting effect that lasts over weeks with minimal systemic toxicity. IntraGel Therapeutics is giving patients a renewed opportunity to combat cancer effectively. We invite the management team at IntraGel Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight your groundbreaking work.